GenSight Biologics
SIGHT.PA
#9662
Rank
$36.98 M
Marketcap
$0.28
Share price
-8.09%
Change (1 day)
-35.40%
Change (1 year)

P/E ratio for GenSight Biologics (SIGHT.PA)

P/E ratio at the end of 2023: -0.8766

According to GenSight Biologics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.490688. At the end of 2023 the company had a P/E ratio of -0.8766.

P/E ratio history for GenSight Biologics from 2016 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2023-0.8766-85.25%
2022-5.94-34.54%
2021-9.0836.35%
2020-6.66188.26%
2019-2.31-9.98%
2018-2.57-51.83%
2017-5.33-13.57%
2016-6.16

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.